Action A222110 PANGEN BIOTECH INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues PanGen Biotech Inc.

Actions

A222110

KR7222110009

Cours en clôture Korea S.E.
Autres places de cotation
 00:00:00 28/06/2024 		Varia. 5j. Varia. 1 janv.
4 970 KRW +0,40 % Graphique intraday de PanGen Biotech Inc. -10,13 % -27,76 %
2023 PanGen Biotech Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2023 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
PanGen Biotech Inc. agreed to acquire PANACEA Inc. from Invites Ventures Co., Ltd., and others
PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
PanGen Biotech Inc. announced that it expects to receive KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
PanGen Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
PanGen Biotech Inc. announced that it has received KRW 3.2 billion in funding from Eugene Investment & Securities Co.,Ltd., Samsung Securities Co., Ltd.
PanGen Biotech Inc. announced that it expects to receive KRW 3.2 billion in funding from Eugene Investment & Securities Co.,Ltd., Samsung Securities Co., Ltd.
CrystalGenomics, Inc. agreed to acquire 20.43% stake in PanGen Biotech Inc. from the group of shareholders for approximately KRW24 billion.
PanGen Biotech Inc. announced that it has received KRW 9.99998571 billion in funding from Huons Co., Ltd. and another investor
PanGen Biotech Inc. announced that it expects to receive KRW 9.99998571 billion in funding from Huons Co., Ltd., and another investor
Huons Lab Forms Partnership with Pangen Biotech to Co-Develop Human Genetic Recombinant Hyaluronidase
PanGen Biotech Inc.(KOSDAQ:A222110) dropped from S&P Global BMI Index
CCM Duopharma Biotech Berhad completed the acquisition of 8.4% stake in PanGen Biotech Inc. from Chemical Company of Malaysia Berhad.
CCM Duopharma Biotech Berhad entered into agreement to acquire PanGen Biotech Inc. from Chemical Company of Malaysia Berhad for KRW 16.4 billion.
Chemical Companies In Talks To Sell Non Core Assets
PanGen Biotech Inc. announced that it has received KRW 18 billion in funding
PanGen Biotech Inc. announced that it expects to receive KRW 18 billion in funding
PanGen Biotech Inc.(KOSDAQ:A222110) added to S&P Global BMI Index
PanGen Biotech Inc. has completed an IPO in the amount of KRW 27.23 billion.
PanGen Biotech Inc. has filed an IPO in the amount of KRW 18.75 billion.
PanGen Biotech Inc. has withdrawn its IPO in the amount of KRW 35.40 billion.
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action A222110
  4. Actualités PanGen Biotech Inc.
  5. Autres langues